Genome-wide splicing QTL analysis identifies causal risk variants for non-small cell lung cancer.

Alternative RNA splicing is an essential mechanism linking genetic variation to human diseases. While the signals from genome-wide association studies(GWAS) have been linked to expression quantitative trait loci(eQTLs) in previous studies,further work is needed to better elucidate the relationship to other genetic regulatory mechanisms,such as splicing QTLs(sQTLs). Here,we performed a genome-wide sQTL analysis to identify variants that might affect RNA splicing in 1,010 non-small cell lung cancer(NSCLC) samples from The Cancer Genome Atlas(TCGA).The identified sQTLs were largely independent of eQTLs and were predominantly enriched in exonic regions,genetic regulatory elements,RNA binding protein(RBP) binding sites, and known NSCLC risk loci. Additionally, target genes affected by sQTLs(sGenes) were involved in multiple processes in cancer,including cell growth,apoptosis,metabolism,immune infiltration,and drug responses,and sGenes were frequently altered genetically in NSCLC. Systematic screening of sQTLs associated with NSCLC risk using GWAS data from 15,474 cases and 12,375 controls identified an sQTL variant rs156697-G allele that was significantly associated with an increased risk of NSCLC. The association between the rs156697-G variant and NSCLC risk was further validated in two additional large population cohorts. The risk variant promoted inclusion of GSTO2 alternative exon 5 and led to higher expression of the GSTO2 full-length isoform(GSTO2-V1) and lower expression of the truncated GSTO2 isoform(GSTO2-V2),which was induced by RBP quaking(QKI). Mechanistically,compared with GSTO2-V1,GSTO2-V2 inhibited NSCLC cells proliferation by increasing S-glutathionylation of AKT1 and thereby functionally blocking AKT1 phosphorylation and activation. Overall,this study provides a comprehensive view of splicing variants linked to NSCLC risk and provides a set of genetic targets with therapeutic potential.